Skip to main content
main-content

Peripheral arterial disease

News

03-20-2019 | Peripheral arterial disease | News

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.

Read more

Related topics

Superior

Related

Opinion

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

Journal articles and book chapters

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

09-28-2017 | Physical activity | Book chapter | Article

Peripheral artery disease and exercise in patients with diabetes

Mays RJ, Whipple MO, Treat-Jacobson D. In: Diabetes and Exercise. Edited by J Reusch et al. Humana Press, Cham, 2017. doi: 10.1007/978-3-319-61013-9_22

06-01-2017 | Diabetic foot | Review | Article

Promoting limb salvage through multi-disciplinary care of the diabetic patient

Salvo NL, Walsh MD, Brewster LP. Curr Treat Options Cardio Med 2017; 19: 55. doi: 10.1007/s11936-017-0547-1

Image Credits